You are here: Industry Insights > Molnupiravir

News List

Interim Results from Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at the European Congress of Clinical Microbiology & Infec drugs
July 16, 2021
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced today the presentation of previously announced Phase 2 interim results from two Phase 2/3 clinical trials (MOVe-OUT and MOVe-IN) of molnupiravir
Cipla, Dr Reddy’s, Emcure, Sun Pharma and Torrent to partner for clinical trial of Molnupiravir expresspharma
June 30, 2021
As per the directive of the SEC of the CDSCO, Dr Reddy’s will conduct the clinical trial and the other four pharma companies will be required to demonstrate equivalence of their product to the product used by Dr Reddy’s in its clinical trial.
CSIR-IICT, NIIST, Suven Pharma sign MoU for Molnupiravir expresspharma
June 11, 2021
The anti-viral drug was initially developed for the treatment of influenza and has been repurposed to treat COVID-19.
Merck signs $1.2bn supply deal with US for antiviral molnupiravir pharmaceutical-technology
June 10, 2021
Merck (MSD) has signed an agreement, valued at about $1.2bn, with the US Government to supply its investigational oral antiviral candidate, molnupiravir (MK-4482) to treat mild to moderate Covid-19.
Natco commences phase-III clinical trial of Molnupiravir for COVID-19 treatment expresspharma
May 24, 2021
Natco Pharma has initiated Phase-III clinical trial of Molnupiravir capsules in India. Its first patient was dosed at Yashoda Hospitals, Hyderabad.
Optimus Pharma gets DCGI nod for Phase III trials of Molnupiravir for COVID-19 treatment expresspharma
May 20, 2021
As per the clinical trial protocol approved, 2500 subjects with mild to moderate COVID-19 will be randomised in the study in a 1:1 ratio to Molnupiravir with standard supportive care or standalone standard supportive care.
MSD signs voluntary licensing agreements with five Indian pharma firms for Molnupiravir expresspharma
April 28, 2021
The agreements have been signed with Cipla, Dr Reddy’s Laboratories, Emcure Pharmaceuticals, Hetero Labs and Sun Pharmaceutical Industries.
NATCO applies to CDSCO for EUA of Molnupiravir capsules to treat COVID-19 expresspharma
April 27, 2021
Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication.
Ridgeback and Merck report preliminary data from Covid-19 trial pharmaceutical-technology
March 09, 2021
Merck and Ridgeback Biotherapeutics have reported preliminary results from a Phase IIa trial of investigational oral antiviral agent molnupiravir EIDD-2801/MK-4482 for Covid-19.

Previous page 1 2 3 4 Next page